Skip to main content
×
Home
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 3
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Hoch, Jeffrey S. Beca, Jaclyn Chamberlain, Charlotte and Chan, Kelvin K.W. 2016. The right amount of chemotherapy in non-curable disease: Insights from health economics. Journal of Cancer Policy,


    Kleijnen, S. Lipska, I. Leonardo Alves, T. Meijboom, K. Elsada, A. Vervölgyi, V. d'Andon, A. Timoney, A. Leufkens, H. G. De Boer, A. and Goettsch, W. G. 2016. Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries. Annals of Oncology, p. mdw233.


    Du, Xianglin L. Parikh, Rohan C. and Lairson, David R. 2015. Racial and geographic disparities in the patterns of care and costs at the end of life for patients with lung cancer in 2007–2010 after the 2006 introduction of bevacizumab. Lung Cancer, Vol. 90, Issue. 3, p. 442.


    ×

Valuing end-of-life care in the United States: the case of new cancer drugs

  • Corinna Sorenson (a1)
  • DOI: http://dx.doi.org/10.1017/S1744133112000217
  • Published online: 19 October 2012
Abstract
Abstract

New cancer therapies offer the hope of improved diagnosis to patients with life-threatening disease. Over the past 5–10 years, a number of specialty drugs have entered clinical practice to provide better systemic therapy for advanced cancers that respond to few therapeutic alternatives. To date, however, such advances have been only modestly effective in extending life and come with a high price tag, raising questions about their value for money, patient access and implications for health care costs. This article explores some of the key issues present in valuing end-of-life care in the United States in the case of advanced cancer drugs, from the difficult trade-offs between their limited health benefits and high costs to the technical, political and social challenges in assessing their value and applying such evidence to inform policy and practice. A number of initial steps are discussed that could be pursued to improve the value of advanced cancer care.

Copyright
Corresponding author
*Correspondence to: Corinna Sorenson, London School of Economics and Political Science, LSE Health, Cowdray House, Houghton Street, London WC2A 2AE, UK. Email: c.sorenson@lse.ac.uk
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

A. P. Abernethy , G. Raman , E. M. Balk , J. M. Hammond , L. A. Orlando , J. L. Wheeler , J. Lau D. C. McCrory (2009), ‘Systematic review: reliability of compendia methods for off-label oncology indications’, Annals of Internal Medicine, 150: 336343.

G. C. Alexander , L. P. Casalino D. O. Meltzer (2003), ‘Patient–physician communication about out-of-pocket costs’, Journal of the American Medical Association, 290(7): 953958.

J. S. Ancker D. Kaufman (2007), ‘Rethinking health numeracy: a multidisciplinary literature review’, Journal of the American Medical Informatics Association, 14: 713721.

P. B. Bach (2009), ‘Limits on Medicare's ability to control rising spending on cancer drugs’, New England Journal of Medicine, 360(6): 626633.

A. E. Barnato , M. B. Herdon , D. L. Anthony , P. M. Gallagher , J. S. Skinner , J. P. W. Bynum E. S. Fisher (2007), ‘Are regional variations in end-of-life care intensity explained by patient preferences? A study of the US Medicare Population’, Medical Care, 45(5): 386393.

K. Chalkidou (2012), ‘Evidence and values: paying for end of life drugs in the British NHS’, Health Economics, Policy and Law.

J. Cohen W. Looney (2010), ‘What is the value of oncology medicines?’, Nature Biotechnology, 28: 11601163.

P. M. Danzon E. Taylor (2010), ‘Drug pricing and value in oncology’, Oncologist, 15(Supplement 1): 2431.

M. Drummond A. Towse (2012), ‘Is it time to consider the role of patient co-payments for pharmaceuticals in Europe?’, European Journal of Health Economics, 13(1): 15.

C. C. Earle , M. B. Landrum , J. M. Souza , B. A. Neville , J. C. Weeks J. Z. Ayanian (2008), ‘Aggressiveness of cancer near the end of life: is it a quality of care issue?’, Journal of Clinical Oncology, 26: 38603866.

R. R. Faden , K. Chalkidou , J. Appleby , H. R. Waters J. Leider (2009), ‘Expensive cancer drugs: a comparison between the United States and the United Kingdom’, Milbank Q, 87: 789819.

T. Fojo C. Grady (2009), ‘How much is life worth: Cetuximab, non-small cell lung cancer, and the $440 billion question’, Journal of National Cancer Institute, 101: 10441048.

N. Freemantle M. F. Drummond (2010), ‘AHRQ Series Commentary 3: The United States addresses comparative effectiveness but not cost-effectiveness through the Effective Health-Care Program’, Journal of Clinical Epidemiology, 63: 479480.

A. M. Garber H. C. Sox (2010), ‘The role of costs in comparative effectiveness research’, Health Affairs, 29(10): 18051811.

A. S. Gerber , E. M. Patashnik , D. Doherty C. Cowling (2010), ‘The public wants information, not broad mandates, from comparative effectiveness research’, Health Affairs, 29(10): 18721881.

D. P. Goldman , A. B. Jena , D. N. Lakdawalla , J. L. Malin , J. D. Malkin E. Sun (2010), ‘The value of specialty oncology drugs’, Health Services Research, 45(1): 115132.

D. Goodman (2011), ‘End-of-life cancer care in Ontario and the United States: quality by accident or quality by design?’, Journal of the National Cancer Institute, 103(11): 12.

S. E. Harrington T. J. Smith (2008), ‘The role of chemotherapy at the end of life: “when is enough, enough”?’, Journal of the American Medical Association, 299: 26672678.

D. U. Himmelstein , D. Thorne , E. Warren S. Woolhandler (2009), ‘Medical bankruptcy in the United States, 2007: results of a national study’, American Journal of Medicine, 122: 741746.

J. Hsu , M. Price , J. Huang , R. Brand V. Fung (2006), ‘Unintended consequences of caps on Medicare drug benefits’, New England Journal of Medicine, 354: 23492359.

M. Jacobson , A. J. O'Malley , C. C. Earle , J. Pakes , P. Gaccione J. P. Newhouse (2006), ‘Does reimbursement influence chemotherapy treatment for cancer patients?’, Health Affairs, 25: 437443.

P. Kim (2007), ‘Costs of cancer: the patient perspective’, Journal of Clinical Oncology, 25(2): 228232.

K. M. Langa , A. M. Fedrick , M. E. Chernew , M. U. Kabeto , K. L. Paisley J. A. Haymen (2004), ‘Out-of-pocket health care expenditures among older Americans with cancer’, Value Health, 7(2): 186194.

J. D. Lubitz G. F. Riley (1993), ‘Trends in Medicare payments in the last year of life’, New England Journal of Medicine, 328(15): 10921096.

J. L. Malin (2010), ‘Wrestling with the high price of cancer care: should we control costs by individuals’ ability to pay or society's willing to pay?’, Journal of Clinical Oncology, 28(20): 32123214.

C. McNeil (2007), ‘Sticker shock sharpens focus on biologics’, Journal of National Cancer Institute, 99(12): 910914.

N. J. Meropol , D. Schrag , T. J. Smith , T. M. Mulvey , R. M. Langdon , D. Blum , P. A. Ubel L. E. Schnipper (2009), ‘American Society of Clinical Oncology guidance statement: the cost of cancer care’, Journal of Clinical Oncology, 27(23): 38683874.

N. J. Meropol K. A. Schulman (2009), ‘Cost of cancer care: issues and implications’, Journal of Clinical Oncology, 25(2): 180186.

C. D. Mullins , R. Montgomery S. Tunis (2010), ‘Uncertainty in assessing value of oncology treatments’, Oncologist, 15(Supplement 1): 5864.

E. Nadler , B. Eckert P. J. Neumann (2006), ‘Do oncologists believe new cancer drugs offer good value?’, Oncologist, 11(2): 9095.

P. J. Neumann , J. A. Palmer , E. Nadler , C. Fang P. Ubel (2010), ‘Cancer therapy costs influence treatment: a national survey of oncologists’, Health Affairs, 29(1): 196202.

P. J. Neumann , E. A. Sandberg , C. M. Bell , P. W. Stone R. H. Chapman (2000), ‘Are pharmaceuticals cost-effective? A review of the evidence’, Health Affairs, 19(2): 92109.

S. D. Pearson P. B. Bach (2010), ‘How Medicare could use comparative effectiveness research in deciding on new coverage and reimbursement’, Health Affairs, 29(10): 17961804.

S. Ramsey A. Schickedanz (2010), ‘How should we define value in cancer care?’, The Oncologist, 15(Supplement 1): 14.

M. D. Rawlins K. Chalkidou (2011), ‘The opportunity cost of cancer care: a statement from NICE’, Lancet Oncology, 12(10): 931932.

L. E. Schnipper , N. J. Meropol D. W. Brock (2010), ‘Value and cancer care: toward an equitable future’, Clinical Cancer Research, 16(24): 60046008.

S. Schrag M. Hanger (2007), ‘Medical oncologists’ views on communicating with patients about chemotherapy costs: a pilot survey’, Journal of Clinical Oncology, 25: 233237.

S. Schrag (2004), ‘The price tag on progress – chemotherapy for colorectal cancer’, New England Journal of Medicine, 351(4): 317319.

A. Schickedanz (2010), ‘Of value: a discussion of cost, communication, and evidence to improve cancer care’, Oncologist, 15(Supplement 1): 7379.

T. J. Smith B. E. Hillner (2011), ‘Bending the cost curve in cancer care’, New England Journal of Medicine, 364(21): 20602065.

T. J. Smith B. E. Hillner (2010), ‘Concrete options and ideas for increasing value in oncology care: the view from one trench’, Oncologist, 15(Supplement 1): 6572.

M. L. Slevin , L. Stubbs , J. J. Plant , P. Wilson , W. M. Gregory , P. J. Armes S. M. Downer (1990), ‘Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public’, British Medical Journal, 300: 14581460.

H. Sox (2009), ‘Evaluating off-label uses of anticancer drugs: time for a change’, Annals of Internal Medicine, 150(5): 353354.

D. P. Sulmasy (2007), ‘Cancer care, money, and the value of life: whose justice? Which rationality?’, Journal of Clinical Oncology, 25(2): 217222.

K. S. Virgo , A. M. Vernava , W. E. Longo , M. E. Kissling , J. C. Lin F. E. Johnson (1995), ‘Cost of patient follow-up after potentially curative colorectal cancer treatment’, Journal of the American Medical Association, 273: 18371841.

U. Wong , O. Hamilton , B. Egleston , K. Salador , C. Murphy N. J. Meropol (2010), ‘Understanding how out-of-pocket expenses, treatment value, and patient characteristics influence treatment choices’, The Oncologist, 15: 566576.

A. A. Wright , B. Zhang , A. Ray , J. W. Mack , E. Trice , T. Balboni , S. L. Mitchell , V. A. Jackson , S. D. Block , P. K. Maciejewski H. G. Prigerson (2008), ‘Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment’, Journal of the American Medical Association, 300: 16651673.

B. Zhang , A. A. Wright , H. A. Huskamp , M. E. Nilsson , M. L. Maciejewski , C. C. Earle , S. D. Block , P. K. Maciejewski H. G. Prigerson (2009), ‘Health care costs in the last week of life: associations with end-of-life conversations’, Archives of Internal Medicine, 169: 480488.

F. K. Tangka , J. G. Trogdon , L. C. Richardson , D. Howard , S. A. Sabatino E. A. Finkelstein (2010), ‘Cancer treatment cost in the United States. Has the burden shifted over time?’, Cancer, 116(14): 34773484.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Health Economics, Policy and Law
  • ISSN: 1744-1331
  • EISSN: 1744-134X
  • URL: /core/journals/health-economics-policy-and-law
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×